A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy
Crossref DOI link: https://doi.org/10.1007/s12032-017-0931-4
Published Online: 2017-03-27
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Konmun, J.
Danwilai, K.
Ngamphaiboon, N.
Sripanidkulchai, B.
Sookprasert, A.
Subongkot, S.
Funding for this research was provided by:
National Research University and Thailand research fund (FC 3.1.14 PhD)
License valid from 2017-03-27